Ionis Pharmaceuticals, Inc. (IONS)

On our desk, the 20% pre-market crash following the CARDIO-TTRansform trial failure triggered heavy options volume and intense retail speculation labeling the selloff an 'opportunity of a lifetime.' However, we are watching strong technical resistance near the $86.74 level very closely before committing fresh capital to long-side exposure.

In our clinic, looking at the data from the Phase 3 ATTR cardiomyopathy study with AstraZeneca, eplontersen missed its primary endpoint for overall reduction in cardiovascular death and recurrent events, although it did show TTR reductions and nominally significant results in the monotherapy subgroup. We are looking forward to the full analysis presentation at the European Society of Cardiology Congress in August.

As a risk manager, I am balancing the recent positive news—such as TRYNGOLZA generating $5 million in early Q2 sales after its late June FDA approval for severe hypertriglyceridemia—against ongoing reimbursement, competition, and commercial execution risks through 2026 and 2027.

From a portfolio management perspective, the July setbacks in ATTR-CM and tominersen created an excessive selloff that heavily discounted Ionis without impairing its wholly owned core assets. With Q2 commercial revenue hitting $119 million and total revenue reaching $268 million, the company's ~$9B valuation and strong liquidity profile offer an attractive entry point for a speculative buy.

From a clinical research standpoint, the completion of patient enrollment in the Phase 3 REVEAL trial for Angelman syndrome represents a crucial milestone that highlights Ionis's deep pipeline execution beyond their cardiovascular and neurology setbacks.